- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02274844
Improving Medication Adherence in the Alabama Black Belt
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Improving medication adherence is one of the greatest challenges in modern medicine. Despite decades of research on the topic, as many as half of patients with chronic diseases are not taking medications as recommended, and costs of nonadherence have been estimated at $290 billion annually. One reason for this persistent finding could be that interventions rarely acknowledge medications within the larger context of the lived experience of illness. Drawing on hundreds of patient interviews, Corbin and Strauss showed that chronic illness is a fundamentally destabilizing influence that forces us to confront the potential limitations of our "new", chronically ill self. Accepting our illness may be a crucial step in embracing medication adherence and other self-management behaviors as ways to restore balance following this disruption. The Corbin and Strauss framework is not often used to develop and test interventions to improve medication adherence, and this is the central objective of this proposal.
Medication adherence is especially critical in regions like rural Alabama, where residents have among the worst health outcomes in the US. Rates of cardiovascular mortality, diabetes and obesity are very high, but resources are scarce and the area's predominately black residents have deep-seated mistrust of the healthcare system (the region includes Tuskegee, site of the infamous syphilis study). This project was designed in collaboration with our community member partners and builds on a 5-year partnership of community-engaged research on diabetes peer coaching interventions and our experience with peer storytelling. The investigators will test the hypothesis that an intervention designed within the Corbin and Strauss framework can improve adherence and health outcomes compared to usual care. Our Aims are:
Aim 1: With our community partners, using qualitative research methods, build on already developed culturally tailored education material to develop the medication adherence intervention. The intervention will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching. Activities include conducting focus groups with patients; creating the DVDs and the coaching intervention protocol; training peer coaches; and pilot testing.
Aim 2: Conduct a randomized controlled trial with 500 individuals with type 2 diabetes and medication nonadherence. The trial will compare the effect of usual care and the intervention on medication adherence and physiologic risk factors including A1c, blood pressure and low density lipoprotein cholesterol (primary outcomes), and quality of life and self-efficacy (secondary outcomes).
This innovative approach would be a major shift in how patients are helped in under resourced areas living with chronic diseases commit to taking medications, improving health and eventually reducing health disparities.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35210
- Univeristy of Alabama at Birmingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adults
- type 2 diabetes
- taking medications for diabetes
- medication non adherent
Exclusion Criteria:
- nursing home residence
- plans to move away in the next year
- advanced illnesses such as hemodialysis, cancer or dementia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Peer Coaching
The intervention participants will receive the Living Well with Diabetes Program.
The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching.
|
The intervention participants will receive the Living Well with Diabetes Program.
The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching
|
|
No Intervention: Usual Care
At enrollment, the investigators will provide an educational DVD on general health and wellness topics including vaccination, cancer screening, osteoporosis and other topics not related to diabetes care.
There will be no peer storytelling on these DVDs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Self Reported Medication Adherence
Time Frame: Baseline, 6 months
|
Patient-reported adherence to medications as a medication adherence score, from 0-3, where a higher score indicates worse adherence.
|
Baseline, 6 months
|
|
Change in Percentage of HbA1c
Time Frame: Baseline, 6 months
|
Hemoglobin A1c test to identify the average amount of glucose (sugar) present in a patient's blood.
|
Baseline, 6 months
|
|
Change in Blood Pressure
Time Frame: Baseline, 6 months
|
2 BP measures were taken 1 minute apart using a LifeSource UA-789 digital blood pressure monitor.
|
Baseline, 6 months
|
|
Change in Low-Density Lipoprotein (LDL) Cholesterol
Time Frame: Baseline, 6 months
|
Finger stick, spectrophotometer to measure cholesterol level.
|
Baseline, 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Quality of Life as Assessed With the Short Form 12- Mental Component
Time Frame: Baseline, 6 months
|
Short Form-12 Mental Component and Physical Component Summary scores range from 0-100; higher scores indicate greater quality of life.
|
Baseline, 6 months
|
|
Change in Quality of Life as Assessed With the Short Form-12- Physical Component
Time Frame: Baseline, 6 months
|
Short Form-12 Mental Component and Physical Component Summary scores range from 0-100; higher scores indicate greater quality of life.
|
Baseline, 6 months
|
|
Change in Medication Use Self-efficacy Score as Measured by SEAMS Scale and the Perceived Diabetes Self-Management Scale, Which is Associated With A1c
Time Frame: Baseline, 6 months
|
Medication use self-efficacy scores for range from 13-39; higher scores indicate higher levels of self-efficacy for medication adherence.
|
Baseline, 6 months
|
|
Change in Diabetes-Specific Quality of Life
Time Frame: Baseline, 6 months
|
Diabetes specific quality of life will be assessed using the validated Diabetes Distress Scale.The DDS is a 17-item instrument that measures diabetes-related emotional distress.
Participants rate the degree to which each item is problematic for them on a 6-point Likert scale, from 1 (no problem) to 6 (serious problem).
A score of 3 or greater = moderate distress.
|
Baseline, 6 months
|
|
Number of Physician Office Visits 6 Months
Time Frame: 6 months
|
6 months
|
|
|
Number of Hospital Stays at 6 Months
Time Frame: 6 months
|
6 months
|
|
|
Number of Emergency Visits at 6 Months
Time Frame: 6 months
|
6 months
|
|
|
Change in Diabetes Medication Counts
Time Frame: Baseline, 6 months
|
Change in number of diabetes medications.
|
Baseline, 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Medication Beliefs- Harm (Beliefs That Medications Are Harmful)
Time Frame: Baseline, 6 months
|
Beliefs about medications questionnaire scores range from 5-25; higher scores indicate stronger beliefs.
|
Baseline, 6 months
|
|
Change in Medication Beliefs- Overuse (Concerns About the Way Doctors Use Medications)
Time Frame: Baseline, 6 months
|
Beliefs about medications questionnaire scores range from 5-25; higher scores indicate stronger beliefs.
|
Baseline, 6 months
|
|
Change in Medication Beliefs-Necessity (Beliefs About the Necessity of Medications)
Time Frame: Baseline, 6 months
|
Beliefs about medications questionnaire scores range from 5-25; higher scores indicate stronger beliefs.
|
Baseline, 6 months
|
|
Change in Medication Beliefs- Concerns (Concerns About the Negative Effects of Medications)
Time Frame: Baseline, 6 months
|
Beliefs about medications questionnaire scores range from 5-25; higher scores indicate stronger beliefs.
|
Baseline, 6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Monika M Safford, MD, Weill Medical College of Cornell University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- PCORI-R-AD-1306-03565
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
State University of New York at BuffaloMedical University of South Carolina; National Institute of Diabetes and Digestive...CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
State University of New York at BuffaloNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Leiden University Medical CenterAndaluz Health ServiceCompletedDiabetes Mellitus | Health Behavior | Self Efficacy | Type2 Diabetes Mellitus | Type1 Diabetes MellitusNetherlands, Spain
-
State University of New York at BuffaloMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Medtronic MiniMed, Inc.RecruitingType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States, Australia, New Zealand
Clinical Trials on Living Well with Diabetes Program
-
University of ArkansasNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Northwestern... and other collaboratorsCompletedDiabetesUnited States
-
Scott A. Irwin, MD, PhDCedars-Sinai Medical Center; ProsomaNot yet recruitingDepression | Anxiety | Supportive Care in CancerUnited States
-
Centers for Disease Control and PreventionUniversity of North Carolina, Chapel Hill; East Carolina UniversityCompleted
-
McMaster UniversityActive, not recruitingLow Back PainCanada
-
University of Sao PauloCompletedSystemic Lupus ErythematosusBrazil
-
Air Liquide Santé InternationalITEC Services; Lincoln Medical and Mental Health CenterCompletedChronic Obstructive Pulmonary Disease (COPD)France, Spain, Germany, Italy
-
Emory UniversityNational Institute on Minority Health and Health Disparities (NIMHD); Centers...Completed
-
Georgia Southern UniversityCompletedDevelopmental Disabilities | Health Education | Community Health Services | Health Services for Persons With DisabilitiesUnited States
-
University of RochesterCompleted
-
Texas A&M UniversityBlue Cross Blue ShieldCompletedDiabetes Mellitus, Type 2United States